A2-73 Sigma-1 Receptor Therapy for Alzheimer’s Sleep Disturbance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a lack of effective drug treatments for insomnia, anxiety, and agitation in patients with Alzheimer's disease, which are exacerbated by sleep disturbances and circadian rhythm dysfunction, contributing to cognitive decline and disease progression.
Innovation Solution
Administering pharmaceutically effective amounts of A2-73, A1-41, or A19-144, optionally with a pharmaceutically acceptable carrier, through various routes including oral, subcutaneous, and topical administration, to treat insomnia, anxiety, or agitation, with doses ranging from 10 mg to 100 mg per day.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of time
If conventional sleep medications are used to treat insomnia in Alzheimer's disease patients, then sleep onset latency may be reduced, but cognitive function deteriorates and falls apart
Solution Approach 1:
The patent changes the pharmacological parameters by using low doses (1-5 mg) of sigma-1 receptor agonists instead of conventional high-dose sleep medications. This parameter change allows improvement of sleep onset latency while preserving cognitive function, as the lower dose range avoids the cognitive deteriorating effects associated with conventional treatments.
Solution Approach 2:
The patent introduces sigma-1 receptor agonists as intermediary substances that mediate between sleep improvement and cognitive preservation. These agonists act as a bridge by selectively activating sigma-1 receptors to promote sleep without the harmful cognitive effects of conventional medications, thus resolving the contradiction between sleep improvement and cognitive function.
2Object-affected harmful factors
If benzodiazepines are used to treat anxiety and agitation in Alzheimer's disease, then anxiety symptoms are reduced, but cognitive function and sleep quality deteriorate
Solution Approach 1:
The patent changes the pharmacological approach by using low-dose sigma-1 receptor agonists instead of conventional benzodiazepine doses. This parameter change enables anxiety symptom reduction while preserving cognitive function and sleep quality, as the lower dose range and different mechanism of action avoid the cognitive deteriorating effects of benzodiazepines.
Solution Approach 2:
The patent employs sigma-1 receptor agonists as intermediary agents that mediate anxiety reduction without the harmful cognitive and sleep effects of benzodiazepines. These agonists provide an alternative mechanism that addresses anxiety symptoms while maintaining cognitive integrity and sleep quality.
3Stability of the object's composition
If high doses of sleep medications are administered to improve sleep efficiency, then sleep fragmentation is reduced, but cognitive function and memory deteriorate
Solution Approach 1:
The patent fundamentally changes the dosage parameter from high doses to low doses (1-5 mg) of sigma-1 receptor agonists. This parameter change enables sleep efficiency improvement through reduced sleep fragmentation while preserving cognitive function and memory, as the low dose range avoids the cognitive deteriorating effects of high-dose conventional medications.
Solution Approach 2:
The patent introduces low-dose sigma-1 receptor agonists as intermediary substances that mediate sleep efficiency improvement without cognitive deterioration. These agonists act as a protective intermediary that improves sleep architecture while preserving cognitive and memory functions, contrasting with conventional high-dose medications that cause cognitive decline.
4Object-affected harmful factors
If conventional medications are used to treat agitation in Alzheimer's disease, then agitation is reduced, but cognitive function and sleep quality deteriorate
Solution Approach 1:
The patent changes the pharmacological parameters by using low doses (1-5 mg) of sigma-1 receptor agonists instead of conventional high-dose agitation medications. This parameter change enables agitation reduction while preserving cognitive function and sleep quality, as the lower dose range and different mechanism avoid the cognitive deteriorating effects of conventional treatments.
Solution Approach 2:
The patent employs low-dose sigma-1 receptor agonists as intermediary agents that mediate agitation reduction without the harmful cognitive and sleep effects of conventional medications. These agonists provide a protective intermediary effect that addresses agitation while maintaining cognitive integrity and sleep quality.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The treatment significantly improves sleep efficiency, reduces anxiety and agitation, stabilizes cognitive function, and lowers systolic blood pressure, as demonstrated by maintained MMSE and ADCS-ADL scores, reduced HAM-D scores, and improved EEG/ERP measures over 31 weeks.
Implementation Method 1
A2-73 is a compound which is believed to bind to muscarinic acetylcholine and sigma-1 receptors with affinities in the low micromolar range
Implementation Method 2
glutamate supply back to neurons by the astrocytes, as a mechanism involved in the fine tuning of sleep oscillations
Implementation Method 3
According to the 'astrocyte-neuron-lactate shuttle hypothesis' (Petit et al., 'Regulation of neuron-astrocyte metabolic coupling across the sleep-wake cycle,'Neurosci 323:135-156 (2016)), lactate coupling with diurnal oscillation of Aβ could be lost after Aβ aggregation
Data Source
AI summary
A2-73 is a useful therapeutic in the treatment of humans suffering from insomnia, anxiety or agitation. Particular attention is made to oral daily doses of from about 10 mg to about 50 mg, with particular reference to about 20 to 30 mg.